Finch Therapeutics

A closed drug company in bankruptcy, selling its gut bacteria patents.

Sold all

What the manager says

In short: Patent-lawsuit bet ended in a bankruptcy sale, earning only a small gain.

Named in

Q2 2026 letter

Owned by

None of the funds we follow

More about Finch Therapeutics

This fund doesn’t file the government report, so share counts aren’t public.

Not investment advice. Holdings come from public SEC reports and the funds’ own letters, and can be up to 4½ months old. How this works